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A B S T R A C T
Background
Trachoma, caused by ocular infection with Chlamydia trachomatis, remains the leading
infectious cause of blindness and in 2002 was responsible for 3.6% of total global blindness.
Although transmission can be successfully interrupted using antibiotics and improvements in
public and personal hygiene, the long-term success of the control programmes advocated by
the World Health Organization are still uncertain. For the complete control and prevention of
trachoma, a vaccine would be highly desirable. Currently there are no licensed vaccines for
trachoma, and no human vaccine trials have been conducted since the 1960s. A barrier to new
attempts to design and introduce a vaccine is the identification of immunologic correlates of
protective immunity or immunopathology. We studied important correlates of the immune
response in a trachoma-endemic population in order to improve our knowledge of this disease.
This is essential for the successful development of a vaccine against both ocular and genital C.
trachomatis infection.
Methods and Findings
We used quantitative real-time PCR for C. trachomatis 16S rRNA to identify conjunctival
infection. The expression of IFN-c, IDO, IL-10, and FOXP3 mRNA transcripts was measured. We
evaluated the role of immune effector and regulatory responses in the control of chlamydial
infection and in the resolution of clinical signs of trachoma in endemic communities in Gambia.
All host transcripts examined were detectable even in normal conjunctiva. The levels of these
transcripts were increased, compared to normal uninfected conjunctiva, when infection was
detected, with or without clinical disease signs. Interestingly, when clinical disease signs were
present in the absence of infection, the expression of a regulatory T cell transcription factor,
FOXP3, remained elevated.
Conclusions
There is evidence of an increase in the magnitude of the local anti-chlamydial cytokine
immune responses with age. This increase is coupled to a decline in the prevalence of infection
and active trachoma, suggesting that effective adaptive immunity is acquired over a number of
years. The anti-chlamydial and inflammatory immune response at the conjunctival surface,
which may control chlamydial replication, is closely matched by counter inflammatory or
regulatory IL-10 expression. Differences in the level of FOXP3 expression in the conjunctiva may
indicate a role for regulatory T cells in the resolution of the conjunctival immune response,
which is important in protection from immunopathology. However, the expression of cytokines
that control chlamydial replication and those that regulate the conjunctival immune response
is not simply juxtaposed; the interaction between the infection and the clinical disease process
is therefore more complex.
The Editors’ Summary of this article follows the references.
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Introduction
Chlamydia trachomatis is the leading infectious cause of
blindness and the most common bacterial sexually trans-
mitted infection. In the United Kingdom, the Health
Protection Agency found that in 45- to 64-y-old women,
rates of chlamydial sexually transmitted infection increased
by 177% between 1995 and 2003 [1]. Trachoma, which is
caused by repeated ocular infection with C. trachomatis, is a
progressive disease, occurring in several stages over the
lifetime of the individual: active trachoma (follicular con-
junctivitis due to C. trachomatis), scarring trachoma, entropion
and trichiasis, and eventually blindness due to corneal
opacity. The immune response elicited, although important
for the control of infection and protection against trachoma
[2–4], is also thought be to responsible, at least in part, for the
tissue damage that ultimately leads to the scarring sequelae of
the disease [5,6].
The processes that lead to the disease and its sequelae are
not fully understood. Examination of the immune response as
the infection unfolds is key to understanding the immuno-
pathogenesis of ocular C. trachomatis infection (OCI). Infec-
tious diseases are often characterised by an incubation
period, in which infection is present without clinical disease;
a period during which both infection and disease are present;
and a period when clinical signs persist after infection has
been cleared [7]. Miller et al. [8] have proposed that OCI
follows such a pattern based on the clinical and micro-
biological observation of trachoma. Earlier work by our
group supports this proposal [9]. We identiﬁed individuals
with infection in the absence of clinical disease, and
individuals with clinical signs in the absence of infection.
Follow-up examination found that individuals who were PCR-
positive but clinically negative were more likely to develop
clinical signs than PCR-negative individuals. Conversely,
clinical signs were twice as likely to have resolved after 1
mo in PCR-negative individuals with disease as in those who
were PCR-positive. Dissection of the immune response in
individuals at these times should identify key components of
the immune response associated with the acquisition or
resolution of infection and clinical signs of trachoma.
Using quantitative PCR it is now possible to study immunity
to OCI in humans at the conjunctival surface. This approach
has been used in studies in trachoma-endemic populations in
Tanzania and Gambia. Bobo et al. [10], in a cross-sectional
study of both adults and children, used a polymerase chain
reaction–enzyme immuno-assay to detect a number of
cytokine transcripts and found a predominantly pro-inﬂam-
matory response in trachoma. Burton et al. [11], in a similar
study in Gambian individuals, found that transcripts associ-
ated with pro-inﬂammatory, anti-inﬂammatory, and ﬁbro-
genic processes were increased in active trachoma. Markers
indicative of a T cell response (interferon gamma [IFN-c],
interleukin [IL]–4, IL-12p40, and perforin) were increased
when chlamydial infection was present. This demonstrated
that, in a complex response, differences associated with
infection and clinical signs could be identiﬁed.
A key factor in the immune response to chlamydial
infection in both humans and animal models is IFN-c [12–
14]. It has been shown, in tissue culture, to limit tryptophan
bioavailability via indoleamine-2,3-dioxygenase (IDO) [15,16].
The action of IFN-c is often opposed by IL-10, a regulatory
cytokine also implicated in chlamydial immunopathogenesis
in murine models [17,18]. IL-10 is produced by a variety of
cells, but has recently been described as an important effector
molecule of some regulatory T cells [19,20]. A role for
Chlamydia-speciﬁc regulatory T cells has not yet been
investigated in trachoma; yet evidence from many chronic
infectious diseases suggests that these important regulators of
the immune response are central to the development of a
balanced and effective immune response, particularly at sites
of infection. Regulatory T cells can be identiﬁed by a
combination of phenotypic markers, the majority of which
are not unique to this cell type. We used the most reliable
marker for naturally occurring and induced regulatory T
cells, forkhead box p3 (FOXP3), as an indicator of regulatory
T cell activity in different phases of infection and disease
caused by OCI.
We present results of a cross-sectional study of OCI and the
clinical signs of trachoma in children living in trachoma-
endemic communities. The expression of IFN-c, IDO, IL-10,
and FOXP3 in the conjunctiva was investigated using
quantitative real-time RT-PCR. The relationship between
expression of human mRNAs, the presence and load of
bacteria at the conjunctival surface, and clinical signs of
active trachoma was examined.
Methods
Ethical Approval
The study and its procedures were approved by the Gambia
Government/Medical Research Council Joint Ethics Commit-
tee and by the Ethics Committee of the London School of
Hygiene and Tropical Medicine.
Recruitment and Follow-Up
School children in nine villages in the Kombo Central and
North Bank Divisions of Gambia were examined for the
clinical signs of trachoma. A subset of 345 children between
the ages of 4 and 15 y were recruited. Children were
examined for signs of active trachoma, and a clinical
diagnosis made according to the World Health Organization
simpliﬁed trachoma grading system [21].
Anaesthetic eye drops (Proxymetacaine 0.5%, Minims,
Chauvin Pharmaceuticals, Romford, United Kingdom) were
administered, and sterile polyester-tipped swabs (Dacron,
Hardwood Products Company, Guildford, Maine, United
States) were used to obtain cellular material from the upper
tarsal conjunctiva of the right eye, by rubbing the swab
horizontally four times against the surface of the conjunctiva,
turning the swab through 908 each time. Conjunctival swabs
were taken for subsequent extraction of RNA; the RNA swab
was collected into RNAlater (Ambion [Europe], Huntingdon,
United Kingdom), stored on ice, and subsequently stored at
20 8C until RNA was extracted.
Children who were found to have intense inﬂammatory
trachoma (TI) were treated upon diagnosis. After the study
each member of the household in which a participant was
resident was treated by administration of a single dose of 20
mg/kg oral azithromycin.
RNA Extraction and RT-PCR
Swabs collected into RNAlater were extracted using the
Qiagen RNeasy Kit (Qiagen, Crawley, United Kingdom),
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according to the manufacturer’s protocol, with the following
modiﬁcation: swabs were transferred to a 2-ml screw-cap tube
containing RLT buffer, they were vortexed vigorously, and
the swab was discarded. A DNase I digestion was carried out
during the extraction process to remove contaminating DNA.
The RNA was eluted into 50 ll of elution buffer and stored at
20 8C. Twenty-ﬁve microlitres of extracted RNA was reverse
transcribed using an oligo-dT15 primer and the Omniscript
reverse transcription system (Qiagen) according to the
manufacturer’s protocol, and the complementary DNA
stored at 20 8C.
Quantitation of Chlamydial 16S Ribosomal RNA
Three microlitres of total RNA extracted from the ocular
swabs was reverse transcribed and ampliﬁed by PCR in a one-
step reaction using primers speciﬁc for chlamydial 16S
ribosomal RNA (rRNA). The Quantitect SYBR Green I One-
Step RT-PCR kit (Qiagen) was used as described previously
[11]. The amount of each chlamydial target per sample was
estimated from standard curves generated with each quanti-
tative RT-PCR assay.
Quantitation of Human mRNA
Total RNA was ﬁrst reverse transcribed using the Omni-
script RT system and 3 ll of the complementary DNA
obtained ampliﬁed by real-time PCR using primers speciﬁc
for IFN-c, IDO, IL-10, FOXP3, and hypoxanthine guanine
phosphoribosyl transferase (HPRT) (Table 1). The copy number
of HPRT and cytokines per sample were estimated from
standard curves included in each assay [11].
Statistical Analysis
The data were managed using Access (Microsoft, Redmond,
Washington, United States) and statistical analyses carried
out using Stata 7 (StataCorp, College Station, Texas, United
States) and Genstat 8 (VSN International, Herts, United
Kingdom). An analysis of variance (ANOVA) with pair-wise
comparisons was used for comparisons of expression of
chlamydial 16S rRNA across clinical trachoma grades.
Individuals were categorised into one of four disease and/or
infection states based on the presence of clinical signs of
disease and the detection of chlamydial 16S rRNA. We
applied the technique of ANOVA as a method to generalise
the t-test to more than two groups. Group differences were
assessed using ANOVA with a covariate adjustment for age. p-
Values from multiple comparisons were adjusted using the
Holm step-down method [22]. Statistical signiﬁcance was
taken to be at the 5% level, but actual p-values are reported
since these are more informative [23].
Canonical variate analysis was used to demonstrate that the
measured cytokine mRNA expression discriminates between
the four disease/infection categories [24,25]. Canonical
variates are linear combinations of the gene transcript levels
that show the most discrimination between the four groups.
For each disease/infection group, the mean canonical score
and its 95% conﬁdence region can be represented in one or
two dimensions, giving a diagrammatic representation of the
differences between the groups based on the gene transcript
levels. Additionally, examination of the linear combinations
may allow the identiﬁcation of those factors that are most
inﬂuential in discriminating between the groups.
The Kruskal-Wallis test was used to examine the association
between age, OCI and active trachoma. The trend of gene
transcript level over age was assessed by allowing different
slopes for the age covariate in each of the four categories of
disease/infection status. A linear regression model was ﬁtted
with terms for age and its interaction with disease/infection
status. Increasingly complex models were ﬁtted until there
was no improvement in ﬁt at the 5% level.
Correlations in transcript abundance were examined using
Spearman’s rank correlation coefﬁcient. Trend lines were
ﬁtted using locally weighted polynomial regression . Locally
weighted polynomial regression is a non-parametric regres-
sion technique that is not affected by extreme points.
Results
Prevalence of Active Trachoma and Chlamydial Infection
A total of 231 males and 114 females were recruited, with a
median age of 8.9 y (4–15 y). The prevalence of active
trachoma in either eye (follicular trachoma [TF] and/or TI)
was 21.5% (74/345), and the prevalence of scarring trachoma
was 5.8% (20/345). The prevalence of chlamydial infection in
the right eye (detection of chlamydial 16S rRNA) was 21.8%
(72/331). Infection could not be assessed in 14 individuals (ten
with normal conjunctiva; four with TF/TI).
In the right eye there was a mismatch between the
observation of clinical signs of disease and the detection of
infection. Fifty-four percent (35/65) of children with active
trachoma (TF and/or TI) did not have evidence of infection,
and 58% (42/72) of infected children had no signs of active
Table 1. Sequences of Primers Used in Quantitative PCR Assays
Gene Primer Sequences Product Size (bp) PCR Annealing Temperature (8C)
IFN-c F 59-ATT CGG TAA CTG ACT TGA ATG TCC-39 129 60
R 59-CTC TTC GAC CTC GAA ACA GC-39
IDO F 59-GAG AAG TTA AAC ATG CTC AGC-39 212 55
R 59-ACA CAG TCT GCA TAA ACC AA-39
IL-10 F 59-TGA GAA CCA AGA CCC AGA CA-39 182 54
R 59-TCA TGG CTT TGT AGA TGC CT-39
FOXP3 F 59-ACC TGG AAG AAC GCC ATC-39 192 58
R 59-TGT TCG TCC ATC CTC CTT TC-39
HPRT F 59-GGC AGT ATA ATC CAA AGA TGG TCA A-39 80 63
R 59-GTC TGG CTT ATA TCC AAC ACT TCG T-39
DOI: 10.1371/journal.pmed.0030266.t001
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clinical disease. Signiﬁcantly higher levels of chlamydial 16S
rRNA were detected in infected individuals who also had
clinical signs of trachoma (scarring trachoma or active
disease) compared to those without clinical signs of disease
(Table 2). The pie charts shown in Figure 1 illustrate even
over a narrow age range (4–15 y) that the percentage of
children with clinical disease (Kruskal-Wallis test: p¼ 0.0005)
and infection (Kruskal-Wallis test: p ¼ 0.03) is reduced with
increased age.
Conjunctival Expression of Cytokine Genes and
Transcription Factors
The medians and inter-quartile ranges of the mRNA
transcript ratios for each gene that was tested are shown in
Figure 2 for each infection/disease group. To improve the
assumptions of ANOVA, the expression ratios for IL-10, IDO,
and IFN-c were log transformed and FOXP3 was square-root
transformed. The overall test by ANOVA for differences
between the infection/disease groups, adjusted for age, was
signiﬁcant at the 5% level for each test transcript. The p-
values for comparisons between the uninfected, clinically
normal individuals and all other groups are shown in Table 3.
Correction for multiplicity was performed using the Holm
step-down method [22], and those values that remained
signiﬁcant at the 5% level are in italics. Because the
prevalence of both active clinical disease signs and infection
declines with age in trachoma-endemic populations, we
adjusted for age in the analysis, i.e., age does not account
for the observed statistical differences.
Individuals with infection both with and without disease
showed signiﬁcantly higher expression of IFN-c compared to
uninfected, clinically normal individuals. There was no
signiﬁcant difference in the level of expression of IFN-c in
clinically normal, uninfected individuals compared to those
without infection but with clinical disease (Figure 2A). A
similar pattern was observed with the expression of IDO
(Figure 2B).
The expression of IL-10, compared to clinically normal,
uninfected individuals, was signiﬁcantly higher only in
individuals with infections coincident with clinical signs of
disease (p¼ 0.003) (Figure 2C). The expression of FOXP3 was
higher in two groups compared to clinically normal, unin-
fected children: those in which infection and clinical signs
were coincident (p¼0.04) and uninfected children with active
trachoma (p ¼ 0.01) (Figure 2D; Table 3).
The expression of IFN-c and IDO were positively correlated
Table 2. Disease Status of the Right Eye and Geometric Mean Chlamydial 16S rRNA Copy Number from the Right Eye among Infected
Individuals Analysed by ANOVA
Disease Status of Right Eye Number in Category Number Infected Geometric Mean
16S rRNA (Copy Number)
95% CI p-Value
Normal 249 38 242 74–792 —
TF 60 25 79,316 18,217–345,344 0.0001
TI 5 5 81,364 555–11,900,000 0.0011
Scarring trachoma 17 4 13,622 224–827,801 0.0356
DOI: 10.1371/journal.pmed.0030266.t002
Figure 1. Prevalence of Ocular Chlamydial Infection and Active Trachoma in the Right Eye by Age
All children in the cohort were categorised into one of the five age bands. The proportion of children in each of the four disease/infection categories
(based on a combination of the presence of clinical signs of active trachoma [TF/TI] and the detection of chlamydial 16S rRNA) is illustrated as pie charts.
DOI: 10.1371/journal.pmed.0030266.g001
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(Figure 3A) in both infected (r ¼ 0.78, 95% conﬁdence
interval [CI] 0.67–0.86, p , 0.0001) and uninfected individuals
(r ¼ 0.49, 95% CI 0.39–0.58, p , 0.0001). The expression of
IDO and pathogen load (chlamydial 16S rRNA) had a weak
positive correlation (r¼0.39, 95% CI 0.09–0.62, p , 0.0001) in
individuals without clinical signs of disease. However, in
individuals with clinical signs there was a weak negative
correlation between IDO expression and pathogen load (r ¼
0.47, 95% CI 0.72 to 0.11, p ¼ 0.014) (Figure 3B). The
expression of IFN-c and IL-10 were also strongly positively
correlated, in both infected individuals (r ¼ 0.82, 95% CI
0.73–0.89, p , 0.0001) and uninfected individuals (r ¼ 0.77,
95% CI 0.68–0.80, p , 0.0001) (Figure 3C).
Canonical Variate Analysis of the Expression of Cytokine
Genes and Transcription Factors
The ﬁrst canonical variate (0.61*IDO  0.63*IL-10 þ
0.084*FOXP3 þ 1.02*IFN-c) weights the contribution of each
cytokine, where the coefﬁcients have been adjusted to allow
for different expression scales. This ﬁrst canonical variate
separates individuals who have clinical signs of disease with
coincident infection from all other groups of individuals
(Figure 4). In the ﬁrst canonical variate, FOXP3 has little
inﬂuence and the effector cytokines dominate. In the second
canonical variate (0.73*IDO  0.43*IL-10 þ 1.03*FOXP3 þ
0.64*IFN-c), FOXP3 is the largest contributor, but all
cytokines have contributions of similar magnitude. Using
both canonical variates separates individuals who are sub-
clinically infected (chlamydial 16S rRNA PCR-positive) from
those who have clinical signs of active trachoma without
infection (Figure 4). These two canonical variates account for
97.3% of the differences between the groups.
Age-Related Modulation of Cytokine Gene and
Transcription Factor Expression: Analysis of Covariance
The amount of variation in gene transcript ratio abun-
dance attributable to the regressions was between 6%
(FOXP3) and 25% (IFN- c). We looked for evidence of
improvement in the magnitude of the immune responses
with age and tested whether lines of different slope for age
Figure 2. Conjunctival Cytokine mRNA Expression in the Right Conjunctivae of Study Participants
RNA was extracted from conjunctival swabs and reverse transcribed, and specific cytokine transcripts were amplified by PCR. Cytokine mRNA expression
was normalized against the housekeeping gene HPRT. The response of each individual is shown with the median value (red bar) and the 25th and 75th
percentiles (blue bars) for each group. Data were tested for significance by ANOVA and adjusted for age. Individuals are categorised using a
combination of the presence of clinical signs of active trachoma (TF/TI) and the detection of chlamydial 16S rRNA. IFN-c (A) and IDO (B) mRNAs were
increased in infected individuals, and they were further increased in those in whom clinical signs coincided with infection compared to clinically normal,
uninfected individuals. IL-10 mRNA (C) was increased only in those who had clinical infections, while FOXP3 mRNA (D) was increased in both clinically
infected and clinically diseased, uninfected individuals.
DOI: 10.1371/journal.pmed.0030266.g002
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Figure 3. Correlations between Right Eye Conjunctival Gene Transcript
Levels Reveal Linked Cytokine Responses and the Relationship to Control
of Pathogen Load
Abundance of IFN-c, IL-10, and IDO relative to HPRT expression after log10
transformation. Correlation coefficients were calculated by Spearman’s
rank correlation and trend lines fitted by locally weighted polynomial
regression.
(A) Strong positive correlation between the conjunctival expression of
IDO and IFN-c in individuals with infection (n¼69) or without infection (n
¼ 238).
(B) Strong positive correlation between the expression of IFN-c and
counter inflammatory IL-10 in infected (n ¼ 69) and uninfected
individuals (n¼ 238).
(C) Relative abundance of IDO and the load of pathogen (chlamydial 16S
rRNA) in the conjunctiva. A weak positive correlation was found between
pathogen load and IDO expression in clinically normal individuals (n ¼
42) (mean pathogen loads are lower in this group; Table 2). In contrast,
the relationship between IDO expression and pathogen load is weakly
negative or absent in individuals with co-incident clinical signs of
trachoma (n ¼ 29) (pathogen loads are highest in this group; Table 2).
CT, C. trachomatis.
DOI: 10.1371/journal.pmed.0030266.g003
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were required within each of the disease/infection strata.
Figure 5 shows the most appropriate signiﬁcant models at the
5% level for each cytokine. Although the regressions were
signiﬁcant, the amount of variation explained was low
because age was the only explanatory variable considered.
There were signiﬁcantly different responses with age within
the disease/infection groups for all cytokines. Separate lines
with signiﬁcantly different gradients were necessary for IDO,
IL-10, and IFN-c, in contrast to FOXP3, where the separate
lines had the same gradient.
The regression model for FOXP3 shows an increase in
FOXP3 expression with increasing age that is independent of
the presence of infection or active trachoma (Figure 5,
bottom right). In contrast, the models for IDO, IFN-c, and IL-
10 show no change in gene expression in the ‘‘normal’’
conjunctiva with age. However, there are increases in
expression with age that are dependent on the presence of
infection and/or disease (Figure 5, top left, top right, and
bottom left).
Discussion
Our data indicate that the greatest chlamydial 16S rRNA
gene expression levels are found in those individuals with the
highest clinical grade of ocular inﬂammation (TI). During
OCI and the appearance of clinical signs both inﬂammatory
(IFN-c) and regulatory (IL-10) cytokine gene expression is
increased. Epithelial conjunctival IDO expression is also
induced, with evidence that the expression levels of these
three genes increase with age. The age-related decline in the
prevalence of OCI and clinical disease is most likely due to
the improvement of these adaptive immune responses. The
conjunctival expression of FOXP3 points to an important
contribution of regulatory T cells, which have thus far not
been described in chlamydial diseases. Interestingly, of the
gene transcripts studied, FOXP3 is the only transcript
expressed above normal levels in individuals with clinical
signs of disease but in whom current infection cannot be
identiﬁed. Further work needs to establish if FOXP3
expression and regulatory T cells in such individuals are
beneﬁcial or exacerbate disease.
Both qualitative DNA-based PCR and quantitative chlamy-
dial 16S rRNA RT-PCR tests identify individuals in whom
there is discordance between infection and clinical signs of
trachoma. It has been established that the clinical signs of
trachoma can persist for long periods of time after infection
can no longer be detected [26,27]. Our data are consistent
with a classical progression of infection—incubation, con-
cordant clinical signs of disease and infection, followed by the
reduction or clearance of infection with residual clinical
disease signs—since we ﬁnd evidence of the existence of these
four phases in study participants [8]. We have revealed that it
is possible to identify discrete patterns of conjunctival mRNA
expression in these phases that are most characteristic of the
immune response in each phase. These data provide evidence
underscoring the importance of the IFN-c response in the
local control of infection and evidence of the presence of
regulatory T cells in human OCI.
In the pre-clinical, incubation phase of infection prior to
disease onset there are low chlamydial loads associated with
an immune proﬁle that is largely type-1 inﬂammatory, with
increased expression of IFN-c and IDO. In a previous study of
the conjunctival cytokine responses of a small group of
individuals followed over a 6-mo period, we found a strong
positive correlation between the amount of chlamydial 16S
rRNA and IFN-c mRNA [28]. We now demonstrate that IDO is
also highly expressed in the conjunctiva. This expression is
greatest in the next phase, when clinical signs and the highest
infection loads are coincident. Like the expression of pro-
inﬂammatory cytokines, IL-10 and FOXP3 expression is also
higher in this phase than in normal conjunctiva. The effect of
IL-10 and the presence of FOXP3 may possibly counteract the
high degree of inﬂammation; however, antagonism of IFN-c-
mediated chlamydial inhibition by IL-10 may reduce the
effectiveness of chlamydial clearance. In humans, host genetic
susceptibility to recurrent genital chlamydial infection and to
the blinding sequelae of ocular infection (trichiasis) are
associated with polymorphism at the IL-10 locus [29,30].
Interestingly, the strong positive correlation between IFN-y
expression and IL-10 in all study participants suggests that
the expression of these genes closely moves hand in hand.
Similar observations have been made in human leishmaniasis
[31], where it was suggested that those with mild forms of
cutaneous disease quickly establish parasite-killing mecha-
nisms and efﬁciently control the inﬂammatory response,
whereas those with disseminated mucosal disease fail to
control the inﬂammatory response [32]. Longitudinal study of
individuals with trachoma should reveal if analogous
responses contribute to exacerbation of conjunctival infec-
tion or effective disease resolution.
These data suggest that the increasing antigen load
stimulates higher levels of IFN-c/IDO, which lag behind
replication of the pathogen but eventually lead to the control
Figure 4. Canonical Variate Analysis Using Right Eye Conjunctival
Cytokine mRNA Expression to Distinguish between Individuals
Canonical variate analysis was used to form two linear combinations of
cytokine mRNA expression that maximized the difference between the
disease/infection groups. The means and 95% CIs of these linear
combinations have been calculated and plotted in two dimensions for
each category, showing that the combinations of cytokine mRNA
expression discriminate between the four categories. The canonical
variates (CV), with coefficients adjusted to allow for different magnitude
scales, are
First CV¼ 0.61*IDO  0.63*IL-10þ 0.084*FOXP3þ 1.02*IFN-c
Second CV ¼0.73*IDO – 0.43*IL-10þ 1.03*FOXP3þ 0.64*IFN-c
DOI: 10.1371/journal.pmed.0030266.g004
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of infection. This is supported by the observation that
infected individuals with clinical signs have very high IDO
transcript levels and relatively lower bacterial loads. An
alternative explanation, supported by the generally positive
correlation between pathogen load and IFN-c/IDO expression
during infection, might be that chlamydial growth evades the
IFN-c/IDO control pathway in the conjunctiva. Currently it is
unclear how ocular serovars of C. trachomatis, which are
deﬁcient in an essential tryptophan synthase gene [33], can
withstand the effects of IFN-c/IDO-mediated tryptophan
depletion in conjunctival epithelial cells.
In trachoma-endemic communities, where most individuals
are repeatedly exposed to OCI, age is a proxy for antigen
experience. In a longitudinal study of individuals of all ages in
an endemic community, we found that disease and infection
episodes were resolved much more rapidly with increasing
age, which explains the observation of a lower prevalence of
clinical signs of disease and of C. trachomatis infection in older
individuals [34]. The age-related resolution of infection was
not explained by age differences in exposure, and presumably
indicated the development of an immune response that
became more effective at clearing infection with cumulative
exposure. The current data demonstrate that, over a
narrower age range of individuals (4- to 15-y-olds), a
reduction in prevalence of disease and infection can still be
observed. In parallel, these ﬁndings provide evidence of age-
related modulation of cytokine expression in response to
disease and infection: older individuals tend to have greater
expression of IFN-c, IDO, and IL-10 in the presence of
infection or disease. Thus, it can be suggested that these
responses represent components, or markers, of the immune
response in the conjunctiva that results in more rapid
clearance of infection and disease with increasing age.
In the ﬁnal phase, when infection has been cleared but
signs of active disease persist, there is evidence of the
presence of regulatory T cells. Regulatory T cells are known
to be involved in the control of a variety of immune
responses, including those responses directed against micro-
bial pathogens [35,36]. The mechanisms by which they
suppress immune responses have been suggested to include
contact-dependent mechanisms, cytokine secretion (in par-
ticular IL-10 and TGF-b), and the modulation of antigen-
presenting cell function (reviewed in [36,37]). In a murine
model of herpetic ocular keratitis, regulatory T cells were
able to control the severity of immunopathological lesions in
the corneal stroma by reducing migration of pathogenic
CD4þ T cells and by reducing the activation of pathogenic T
cells, in an IL-10-dependent manner [38].
We found that in OCI, increased FOXP3 expression at the
site of infection could be an indicator of recruitment of
regulatory T cells. One of the likely consequences of this
recruitment is that the regulatory T cells limit the inﬂamma-
tory response and the extent of extracellular matrix break-
down (possibly by mechanisms similar to that of the herpetic
keratitis model [38,39]), thus limiting tissue damage and
encouraging extracellular matrix repair after the damage
caused by cellular inﬁltration and lymphoid follicle forma-
tion.
Levels of FOXP3 were higher in infection and disease, but
they also increased with age in both infected and normal
Figure 5. Age Modulation on Right Eye Conjunctival mRNA Expression: Analysis of Covariance
Individuals were categorised using a combination of the presence of clinical signs of active trachoma (TF/TI) and the detection of chlamydial 16S rRNA.
Regression models were fitted for the expression of each human mRNA assayed and age (years) within each category. The regression lines for
individuals in each category are shown for each of the mRNAs, IDO (top left), IFN-c (bottom left), IL-10 (top right), and FOXP3 (bottom right). Green line:
clinically normal, uninfected individuals; blue line: clinically normal, infected individuals; red line: clinically diseased, infected individuals; and orange
line: clinically diseased, uninfected individuals.
DOI: 10.1371/journal.pmed.0030266.g005
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conjunctiva. This ﬁnding does not indicate that the implied
regulatory T cell activity is not C. trachomatis related or
disease speciﬁc. Rather it may be a feature of the measure-
ment of a transcription factor or an indication that in the
conjunctiva the dynamics and magnitude of the adaptive
regulatory T cell response are different to that of cytokine
gene expression.
There are currently conﬂicting opinions on whether T cell
regulation declines or increases with age, and what contri-
bution this regulation may have to immune senescence or
immune dysfunction. In some models of autoimmune disease,
onset of auto-reactivity, which is related to age, coincides
with the decline of foxp3-expressing cells in the tissues [40]. In
other diseases, however, such as inﬂammatory bowel disease,
the mucosal lesions contain increased FOXP3þ cells and
transcripts even though the compartment of peripheral
FOXP3þ cells is reduced [41]. Recently, a subset of cells
termed natural naı¨ve FOXP3þ regulatory T cells present in
the peripheral blood were also shown to decline with age [40],
but others have found that the number of peripheral
CD4þCD25high cells with demonstrable regulatory T cell
function increased with age [42]. In order to resolve these
conﬂicts, further work is required that clearly identiﬁes the
phenotype of each regulatory T cell population and its
functional status in relation to its anatomical location.
Studying immune responses at the conjunctival surface in a
large number of individuals presents many problems, includ-
ing limitations in the type of sample that can be obtained.
This study used expression of immune response genes to
overcome some of these limitations. This is a sensitive
technique, amenable to repeated sampling and applicable
to large numbers of samples. In addition, it provides greater
sensitivity for detecting some of the markers assayed and in
some cases is the only means available for detection.
However, the nature of the sampling technique precludes
an assessment of the relative contribution of different cell
types to the production of these cytokines and other factors.
This study highlights the distinct immunological proﬁles,
inﬂammatory and regulatory, that may be associated with the
different phases of OCI and disease. These proﬁles may, by
virtue of their duration, contribute to protection from
infection or to the immunopathology induced by infection.
Longitudinal follow-up studies should seek to verify their
contribution.
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Editors’ Summary
Background. Trachoma is the leading infectious cause of blindness
worldwide. Six million people—most of whom live in crowded,
unhygienic conditions with limited water supplies—are blind because
of repeated eye infections with Chlamydia trachomatis. This bacterium
passes easily from person to person on hands or clothing and is also
spread by flies. Successive infections starting in childhood cause
progressive scarring of the inside of the eyelid. Eventually, the eyelashes
turn inwards and rub painfully over the front of the eye (the cornea). This
causes corneal scarring, loss of corneal transparency, and, finally,
irreversible loss of sight, usually in adulthood. C. trachomatis infections
can be prevented by improving personal hygiene and by reducing fly
breeding sites, and they can be treated with antibiotics. In addition, early
scarring of the eyelid and turned-in eyelashes can be treated surgically.
Why Was This Study Done? Through the above interventions, the
World Health Organization hopes to eliminate trachoma by 2020, but a
vaccine might also be necessary. To develop a vaccine, the human
immune response to C. trachomatis needs to be better understood. As
with other diseases, the immune response to C. trachomatis includes a
pro-inflammatory side, which activates immune cells to attack the
bacteria, and a regulatory side, which keeps the pro-inflammatory
responses in check. The balance between these two sides is not perfect,
however. Although the immune response deals with C. trachomatis
infections efficiently, it also causes some of the tissue damage that leads
to scarring and loss of sight. In this study, the researchers have
investigated the human immune response to C. trachomatis to provide
immunological information that might help vaccine development.
What Did the Researchers Do and Find? The researchers examined
school children living in Gambia, where trachoma is very common, for
clinical signs of active trachoma (for example, red or swollen eyelids). To
find out which children were infected with C. trachomatis, the
researchers collected a few cells from the surface of their eyes and
looked for a ribonucleic acid (RNA) molecule that is only made by C.
trachomatis. The researchers also looked in these samples for human
messenger RNA (mRNA) molecules that are made during pro-inflamma-
tory and regulatory immune responses.
The children formed four groups based on infection with C.
trachomatis and clinical signs. Some children—particularly the older
ones—were uninfected and had no clinical signs. Others were infected
but showed no clinical signs—these children were incubating the
bacteria. Some were infected and had clinical disease; these children had
the highest bacterial loads. Finally, children recovering from an infection
carried no bacteria but still had some clinical signs.
The researchers detected different types of immune response in
each of these groups. Children incubating the bacteria had a strong pro-
inflammatory response—their immune systems were trying to fight off
infection. The pro-inflammatory response was even stronger in the
infected children with clinical signs, but now the regulatory response
had also increased, presumably to limit inflammation. In children in the
recovery phase, only regulatory immune cells, which were making an
mRNA from a gene called FOXP3, remained active.
What Do These Findings Mean? The relative rarity of infections and
active disease in older children together with indications of a more active
immune response to infection indicates that protective immunity to C.
trachomatis is acquired through repeated exposure to it. This bodes well
for the development of a vaccine, which would speed up the acquisition
of this natural immunity. Furthermore, the new information about
immune responses at different stages of infection with C. trachomatis
should help in vaccine design. The findings need to be confirmed by
tracking immune responses in individual children during episodes of
infection, but could then be used to help design vaccines that produce
good protective immunity against C. trachomatis without causing too
much collateral tissue damage. The current results suggest, for example,
that regulatory immune cells are important in limiting the inflammatory
response, so vaccine developers may need to ensure that their vaccines
stimulate the production of this sort of cell as well as of the pro-
inflammatory cells needed to clear the infection.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030266.
 NHS Direct Online patient information on trachoma
 World Health Organization information on trachoma and its
elimination
 US Centers for Disease Control and Prevention general information on
trachoma
 MedlinePlus encyclopedia entry on trachoma
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